Beta-Arrestin Effectors for Cardiovascular Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs targeting GPCRs for treating cardiovascular diseases like acute heart failure and acute hypertensive crisis are limited in effectively modulating signaling pathways related to blood pressure and fluid homeostasis.
Innovation Solution
Development of novel β-arrestin effectors with specific peptide or peptide mimetic structures that act as agonists of β-arrestin/GRK-mediated signal transduction via the AT1 angiotensin receptor, providing therapeutic benefits by stimulating targeted signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional GPCR drugs are used to treat cardiovascular diseases, then blood pressure and fluid homeostasis are modulated, but the ability to effectively target specific signaling pathways is limited
Solution Approach 1:
The patent segments the GPCR signaling process by developing compounds that selectively activate different downstream pathways (beta-arrestin recruitment versus G-protein activation) from the same receptor (AT1R). This allows independent modulation of distinct signaling cascades, enabling precise control over cardiovascular responses through pathway-specific drug design
Solution Approach 2:
The invention changes the pharmacological parameters of AT1R modulation by creating ligands with biased signaling profiles. These compounds alter the relative activation levels of different signaling pathways (changing the parameter distribution of receptor outcomes), thereby achieving reliable and versatile pathway modulation from a single receptor target
2Reliability
If novel β-arrestin effectors are developed to target specific signaling pathways, then therapeutic benefit is improved, but drug development complexity increases
Solution Approach 1:
The patent achieves universality by designing a single AT1R-targeted compound platform that can produce multiple therapeutic effects through biased signaling. The same molecular scaffold can selectively engage different downstream pathways (beta-arrestin, G-proteins) depending on structural modifications, providing multi-functional therapeutic benefits from a unified drug development approach
Solution Approach 2:
The invention uses beta-arrestin as an intermediary molecule to transmit signals from the AT1R to downstream effectors. By designing compounds that preferentially recruit beta-arrestin, the patent creates a controllable signaling intermediary that mediates therapeutic effects while simplifying the overall drug-receptor-response relationship
Data Source
AI summary
This application describes a family of compounds acting as ß-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.